Feng Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Feng Yan has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- David J. Curtis
Monash University
7 shared publications - John E. Pimanda
University of New South Wales
6 shared publications - Julie A. I. Thoms
School of Biomedical Sciences, University of New South Wales, Sydney, Australia
6 shared publications - Le Ying
Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research Clayton Victoria Australia
6 shared publications - Dakang Xu
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
5 shared publications - Jake Olivier
School of Mathematics and Statistics, UNSW, Sydney, New South Wales, Australia
5 shared publications
Latest Publications
- Open Access
Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell Remodeling
Myelodysplastic syndromes (MDS) are driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs), leading to clonal expansion and ineffective hematopoiesis. Hypomethylating agents (HMAs; azacitidine or decitabine) are the standard of care for higher-risk MDS. However, their effects on the bone marrow (BM) microenvironment, and the extent to which these changes correlate with clinical response, remain poorly understood. We performed longitudinal analyses of BM aspirates, trephine biopsies, and peripheral blood samples from MDS patients treated with azacitidine in a clinical trial ( NCT03493646 ), integrating CyTOF, 5′ single-cell RNA and TCR sequencing, plasma proteomics, and multiplex immunofluorescence microscopy to characterize changes associated with azacitidine response. Clinical responders showed expansion of GzmB⁺CD56⁺CD8⁺ T cells together with increased type I and type II interferon signaling within the T-cell compartment. Responders also exhibited marked alterations in circulating platelet– and myeloid-derived factors with the potential to remodel the BM niche. Spatial analyses revealed expansion of “neighborhoods” enriched for CXCL12-abundant reticular cells and CD8 T cells in responders, whereas HSPC-enriched neighborhoods were largely unchanged. In contrast, several HSPC-enriched neighborhoods expanded in non-responders. These microenvironmental changes were accompanied by evidence of enhanced myelopoiesis in clinical responders. Our findings support a model in which azacitidine response extends beyond direct effects on malignant hematopoietic cells to involve coordinated remodeling of the BM microenvironment which may be reinforced by platelet– and myeloid-derived signals that establish a feed-forward circuit promoting productive hematopoiesis. One Sentence Summary: Longitudinal bone marrow profiling reveals stromal and immune correlates of azacitidine response in myelodysplastic syndrome.
Open AccessAzacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell Remodeling
Myelodysplastic syndromes (MDS) are driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs), leading to clonal expansion and ineffective hematopoiesis. Hypomethylating agents (HMAs; azacitidine or decitabine) are the standard of care for higher-risk MDS. However, their effects on the bone marrow (BM) microenvironment, and the extent to which these changes correlate with clinical response, remain poorly understood. We performed longitudinal analyses of BM aspirates, trephine biopsies, and peripheral blood samples from MDS patients treated with azacitidine in a clinical trial ( NCT03493646 ), integrating CyTOF, 5′ single-cell RNA and TCR sequencing, plasma proteomics, and multiplex immunofluorescence microscopy to characterize changes associated with azacitidine response. Clinical responders showed expansion of GzmB⁺CD56⁺CD8⁺ T cells together with increased type I and type II interferon signaling within the T-cell compartment. Responders also exhibited marked alterations in circulating platelet– and myeloid-derived factors with the potential to remodel the BM niche. Spatial analyses revealed expansion of “neighborhoods” enriched for CXCL12-abundant reticular cells and CD8 T cells in responders, whereas HSPC-enriched neighborhoods were largely unchanged. In contrast, several HSPC-enriched neighborhoods expanded in non-responders. These microenvironmental changes were accompanied by evidence of enhanced myelopoiesis in clinical responders. Our findings support a model in which azacitidine response extends beyond direct effects on malignant hematopoietic cells to involve coordinated remodeling of the BM microenvironment which may be reinforced by platelet– and myeloid-derived signals that establish a feed-forward circuit promoting productive hematopoiesis. One Sentence Summary: Longitudinal bone marrow profiling reveals stromal and immune correlates of azacitidine response in myelodysplastic syndrome.
- Open Access
MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs
Our previous mouse genetic studies showed that loss of the transcription repressor MNT enhanced apoptosis of premalignant lymphoid cells over-expressing MYC and inhibited lymphoma development. Here, we have explored the consequences of inducing Mnt deletion in fully malignant lymphoma cells. MNT loss provoked apoptosis of p53 wt and, albeit more slowly, p53 mutant Eμ-Myc lymphoma cells, preceded by elevated levels of major BH3-only proteins BIM and PUMA. By inhibiting apoptosis, we showed that MNT loss also impaired cell cycling and increased senescence. Eμ-Myc lymphoma cells depend on the BCL-2 ortholog MCL-1 for survival and expansion and, importantly, MNT loss enhanced their sensitivity to the MCL-1 inhibitor S63845 and to several chemotherapeutic agents. In BCL-2-overexpressing Eμ-Myc lymphoma cells, which model aggressive human ‘Double Hit Lymphomas’, MNT loss enhanced sensitivity to the BCL-2 inhibitor ABT-199, even after BAX loss. Furthermore, MNT deletion improved drug responses of two long-established Burkitt Lymphoma cell lines. SIGNIFICANCE: This study establishing the MNT dependency of Eμ-Myc lymphoma cells and demonstrating that MNT loss enhances their sensitivity to apoptosis induced by conventional chemotherapeutics and BH3 mimetic drugs provides strong proof-of-concept for developing MNT inhibitors to improve treatment of MYC-driven blood cancers.
Open AccessMNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs
Our previous mouse genetic studies showed that loss of the transcription repressor MNT enhanced apoptosis of premalignant lymphoid cells over-expressing MYC and inhibited lymphoma development. Here, we have explored the consequences of inducing Mnt deletion in fully malignant lymphoma cells. MNT loss provoked apoptosis of p53 wt and, albeit more slowly, p53 mutant Eμ-Myc lymphoma cells, preceded by elevated levels of major BH3-only proteins BIM and PUMA. By inhibiting apoptosis, we showed that MNT loss also impaired cell cycling and increased senescence. Eμ-Myc lymphoma cells depend on the BCL-2 ortholog MCL-1 for survival and expansion and, importantly, MNT loss enhanced their sensitivity to the MCL-1 inhibitor S63845 and to several chemotherapeutic agents. In BCL-2-overexpressing Eμ-Myc lymphoma cells, which model aggressive human ‘Double Hit Lymphomas’, MNT loss enhanced sensitivity to the BCL-2 inhibitor ABT-199, even after BAX loss. Furthermore, MNT deletion improved drug responses of two long-established Burkitt Lymphoma cell lines. SIGNIFICANCE: This study establishing the MNT dependency of Eμ-Myc lymphoma cells and demonstrating that MNT loss enhances their sensitivity to apoptosis induced by conventional chemotherapeutics and BH3 mimetic drugs provides strong proof-of-concept for developing MNT inhibitors to improve treatment of MYC-driven blood cancers.
- Open Access
Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapy
Progressive somatic mutations in hematopoietic stem cells (HSCs) drive the development of myelodysplastic neoplasms (MDS). Hypomethylating agents such as azacitidine (AZA) can improve blood counts and reduce blasts, although responses are rarely durable. Determinants of AZA response are complex and incompletely understood, although accumulating evidence suggests that epigenetic rewiring of mutated HSCs underlies improved hematopoietic output. Using single cell multiomics on longitudinal bone marrow samples, we show that AZA responsiveness involves expansion of cells with transcriptomic profiles shared with hematopoietic stem and progenitor cells (HSPCs) from healthy donors. These regenerating cells are depleted of copy number variations and of TP53 mutations. We also identify patient-restricted cell populations, some of which recede through transcriptional restoration or AZA cytotoxicity, and others which expand, regardless of initial clinical response, and dominate at progression. Individual patients carried multiple patient-restricted populations which had unique surface immunophenotypes and were genetically distinct. Strikingly, sorted cells from in vivo progression clones that were AZA-refractive in patients regained AZA-sensitivity when cultured in vitro , suggesting that lack of AZA response at the cellular level can be modulated by cell-extrinsic factors in vivo . Overall, we find that AZA response involves partial hematopoietic regeneration via functional differentiation of mutated, but not cytogenetically abnormal HSPCs, and that persistence of AZA-refractive sub-populations contributes to eventual disease progression.
Open AccessSingle cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapy
Progressive somatic mutations in hematopoietic stem cells (HSCs) drive the development of myelodysplastic neoplasms (MDS). Hypomethylating agents such as azacitidine (AZA) can improve blood counts and reduce blasts, although responses are rarely durable. Determinants of AZA response are complex and incompletely understood, although accumulating evidence suggests that epigenetic rewiring of mutated HSCs underlies improved hematopoietic output. Using single cell multiomics on longitudinal bone marrow samples, we show that AZA responsiveness involves expansion of cells with transcriptomic profiles shared with hematopoietic stem and progenitor cells (HSPCs) from healthy donors. These regenerating cells are depleted of copy number variations and of TP53 mutations. We also identify patient-restricted cell populations, some of which recede through transcriptional restoration or AZA cytotoxicity, and others which expand, regardless of initial clinical response, and dominate at progression. Individual patients carried multiple patient-restricted populations which had unique surface immunophenotypes and were genetically distinct. Strikingly, sorted cells from in vivo progression clones that were AZA-refractive in patients regained AZA-sensitivity when cultured in vitro , suggesting that lack of AZA response at the cellular level can be modulated by cell-extrinsic factors in vivo . Overall, we find that AZA response involves partial hematopoietic regeneration via functional differentiation of mutated, but not cytogenetically abnormal HSPCs, and that persistence of AZA-refractive sub-populations contributes to eventual disease progression.
- Top Cited PapersOpen Access
- 13 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
Hypomethylating agents are frontline therapies for myelodysplastic neoplasms (MDS), yet clinical responses remain unpredictable. We conducted a phase 2 trial comparing injectable and oral azacitidine (AZA) administered over one or three weeks per four-week cycle, with the primary objective of investigating whether response is linked to in vivo drug incorporation or DNA hypomethylation. Our findings show that injection results in higher drug incorporation, but lower DNA demethylation per cycle, while global DNA methylation levels in mononuclear cells are comparable between responders and non-responders. However, hematopoietic stem and progenitor cells (HSPCs) from responders exhibit distinct baseline and early treatment-induced CpG methylation changes at regulatory regions linked to tissue patterning, cell migration, and myeloid differentiation. By cycle six—when clinical responses typically emerge—further differential hypomethylation in responder HSPCs suggests marrow adaptation as a driver of improved hematopoiesis. These findings indicate that intrinsic baseline and early drug-induced epigenetic differences in HSPCs may underlie the variable clinical response to AZA in MDS.
- 13 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Top Cited PapersOpen AccessClinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
Hypomethylating agents are frontline therapies for myelodysplastic neoplasms (MDS), yet clinical responses remain unpredictable. We conducted a phase 2 trial comparing injectable and oral azacitidine (AZA) administered over one or three weeks per four-week cycle, with the primary objective of investigating whether response is linked to in vivo drug incorporation or DNA hypomethylation. Our findings show that injection results in higher drug incorporation, but lower DNA demethylation per cycle, while global DNA methylation levels in mononuclear cells are comparable between responders and non-responders. However, hematopoietic stem and progenitor cells (HSPCs) from responders exhibit distinct baseline and early treatment-induced CpG methylation changes at regulatory regions linked to tissue patterning, cell migration, and myeloid differentiation. By cycle six—when clinical responses typically emerge—further differential hypomethylation in responder HSPCs suggests marrow adaptation as a driver of improved hematopoiesis. These findings indicate that intrinsic baseline and early drug-induced epigenetic differences in HSPCs may underlie the variable clinical response to AZA in MDS.
- Open Access
Towards accurate, reference-free differential expression: A comprehensive evaluation of long-read de novo transcriptome assembly
Long-read RNA sequencing has significantly advanced transcriptomics by enabling the full length of transcripts to be assessed. However, current analysis methods often depend on a high-quality reference genome and gene annotation. Recently, de novo assembly methods have been developed to utilise long-read data in cases where a reference genome is unavailable, such as in non-model organisms. Despite the potential of these tools, there remains a lack of benchmarking and established protocols for optimal reference-free, long-read transcriptome assembly and differential expression analysis. Here, we comprehensively evaluate the current state-of-the-art long-read de novo transcriptome assembly tools, RATTLE, RNA-Bloom2 and isONform, and compare their performance to one of the leading short-read assemblers, Trinity. We assess various metrics, including assembly quality and computational efficiency, across a range of datasets, which include simulated data and spike-in sequin transcripts, where ground truth is known, and real data from human and pea ( Pisum sativum ) samples, using a reference-based approach to define truth. To represent contemporary analysis scenarios, the datasets cover depths from 6 million to 60 million reads, Oxford Nanopore Technologies (ONT) cDNA, ONT direct RNA and Pacific Biosciences (PacBio) 10x single-cell sequencing. Critically, we assessed the downstream impact of assembly choice on the detection of differential gene and transcript expression. Our results confirm that long reads generate longer assembled transcripts than short-reads for reference-free analysis, though limitations remain compared to reference-guided approaches, and suggest scope for improved accuracy and reduced redundancy. Of the de novo pipelines, RNA-Bloom2, coupled with Corset for transcript clustering, was the best performing in terms of both accuracy and computational efficiency. Our findings offer guidance when selecting the most effective strategy for long-read differential expression analysis, when a high-quality reference genome is unavailable.
Open AccessTowards accurate, reference-free differential expression: A comprehensive evaluation of long-read de novo transcriptome assembly
Long-read RNA sequencing has significantly advanced transcriptomics by enabling the full length of transcripts to be assessed. However, current analysis methods often depend on a high-quality reference genome and gene annotation. Recently, de novo assembly methods have been developed to utilise long-read data in cases where a reference genome is unavailable, such as in non-model organisms. Despite the potential of these tools, there remains a lack of benchmarking and established protocols for optimal reference-free, long-read transcriptome assembly and differential expression analysis. Here, we comprehensively evaluate the current state-of-the-art long-read de novo transcriptome assembly tools, RATTLE, RNA-Bloom2 and isONform, and compare their performance to one of the leading short-read assemblers, Trinity. We assess various metrics, including assembly quality and computational efficiency, across a range of datasets, which include simulated data and spike-in sequin transcripts, where ground truth is known, and real data from human and pea ( Pisum sativum ) samples, using a reference-based approach to define truth. To represent contemporary analysis scenarios, the datasets cover depths from 6 million to 60 million reads, Oxford Nanopore Technologies (ONT) cDNA, ONT direct RNA and Pacific Biosciences (PacBio) 10x single-cell sequencing. Critically, we assessed the downstream impact of assembly choice on the detection of differential gene and transcript expression. Our results confirm that long reads generate longer assembled transcripts than short-reads for reference-free analysis, though limitations remain compared to reference-guided approaches, and suggest scope for improved accuracy and reduced redundancy. Of the de novo pipelines, RNA-Bloom2, coupled with Corset for transcript clustering, was the best performing in terms of both accuracy and computational efficiency. Our findings offer guidance when selecting the most effective strategy for long-read differential expression analysis, when a high-quality reference genome is unavailable.
- Open Access
- 23 January 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (3) , 577-589
Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) is an immature subtype of T-cell acute lymphoblastic leukemia (T-ALL) commonly show deregulation of the LMO2-LYL1 stem cell transcription factors, activating mutations of cytokine receptor signaling, and poor early response to intensive chemotherapy. Previously, studies of the Lmo2 transgenic mouse model of ETP-ALL identified a population of stem-like T-cell progenitors with long-term self-renewal capacity and intrinsic chemotherapy resistance linked to cellular quiescence. Here, analyses of Lmo2 transgenic mice, patient-derived xenografts, and single-cell RNA-sequencing data from primary ETP-ALL identified a rare subpopulation of leukemic stem cells expressing high levels of the cytokine receptor FLT3. Despite a highly proliferative state, these FLT3-overexpressing cells had long-term self-renewal capacity and almost complete resistance to chemotherapy. Chromatin immunoprecipitation and assay for transposase-accessible chromatin sequencing demonstrated FLT3 and its ligand may be direct targets of the LMO2 stem-cell complex. Media conditioned by Lmo2 transgenic thymocytes revealed an autocrine FLT3-dependent signaling loop that could be targeted by the FLT3 inhibitor gilteritinib. Consequently, gilteritinib impaired in vivo growth of ETP-ALL and improved the sensitivity to chemotherapy. Furthermore, gilteritinib enhanced response to the BCL2 inhibitor venetoclax, which may enable “chemo-free” treatment of ETP-ALL. Together, these data provide a cellular and molecular explanation for enhanced cytokine signaling in LMO2-driven ETP-ALL beyond activating mutations and a rationale for clinical trials of FLT3 inhibitors in ETP-ALL.
- 23 January 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (3) , 577-589
Open AccessTargeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) is an immature subtype of T-cell acute lymphoblastic leukemia (T-ALL) commonly show deregulation of the LMO2-LYL1 stem cell transcription factors, activating mutations of cytokine receptor signaling, and poor early response to intensive chemotherapy. Previously, studies of the Lmo2 transgenic mouse model of ETP-ALL identified a population of stem-like T-cell progenitors with long-term self-renewal capacity and intrinsic chemotherapy resistance linked to cellular quiescence. Here, analyses of Lmo2 transgenic mice, patient-derived xenografts, and single-cell RNA-sequencing data from primary ETP-ALL identified a rare subpopulation of leukemic stem cells expressing high levels of the cytokine receptor FLT3. Despite a highly proliferative state, these FLT3-overexpressing cells had long-term self-renewal capacity and almost complete resistance to chemotherapy. Chromatin immunoprecipitation and assay for transposase-accessible chromatin sequencing demonstrated FLT3 and its ligand may be direct targets of the LMO2 stem-cell complex. Media conditioned by Lmo2 transgenic thymocytes revealed an autocrine FLT3-dependent signaling loop that could be targeted by the FLT3 inhibitor gilteritinib. Consequently, gilteritinib impaired in vivo growth of ETP-ALL and improved the sensitivity to chemotherapy. Furthermore, gilteritinib enhanced response to the BCL2 inhibitor venetoclax, which may enable “chemo-free” treatment of ETP-ALL. Together, these data provide a cellular and molecular explanation for enhanced cytokine signaling in LMO2-driven ETP-ALL beyond activating mutations and a rationale for clinical trials of FLT3 inhibitors in ETP-ALL.
- Open Access
- 16 August 2024
- Published by Springer Nature in Research Square
Targeting LMO2-induced autocrine FLT3 signalling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) is characterised by aberrant expression of the LMO2-LYL1 stem-cell transcription factor complex, activating mutations of cytokine receptor signalling and poor response to intensive chemotherapy. Previously, studies of the Lmo2 transgenic mouse model of ETP-ALL identified a population of stem-like T-cell progenitors with long-term self-renewal capacity and intrinsic chemoresistance linked to cellular quiescence. Here, analyses of Lmo2 transgenic mice, patient-derived xenografts and single-cell RNA-sequencing data from primary ETP-ALL identified a rare subpopulation of leukemic stem cells expressing high levels of the cytokine receptor FLT3. Despite a highly proliferative state, these FLT3-overexpressing cells had long-term self-renewal capacity and almost complete resistance to chemotherapy. We found that FLT3 and its ligand may be direct targets of the LMO2 stem-cell complex, thereby establishing an autocrine FLT3 signalling loop that could be targeted by the FLT3 inhibitor gilteritinib. Consequently, gilteritinib impaired in vivo growth of ETP-ALL and improved the response to chemotherapy. Furthermore, gilteritinib synergized with the BCL2 inhibitor venetoclax, which may enable ‘chemo-free’ treatment of ETP-ALL. Together, these data provide a cellular and molecular explanation for enhanced cytokine signalling in LMO2-driven ETP-ALL beyond activating mutations and a rationale for clinical trials of FLT3 inhibitors in ETP-ALL.
- 16 August 2024
- Published by Springer Nature in Research Square
Open AccessTargeting LMO2-induced autocrine FLT3 signalling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) is characterised by aberrant expression of the LMO2-LYL1 stem-cell transcription factor complex, activating mutations of cytokine receptor signalling and poor response to intensive chemotherapy. Previously, studies of the Lmo2 transgenic mouse model of ETP-ALL identified a population of stem-like T-cell progenitors with long-term self-renewal capacity and intrinsic chemoresistance linked to cellular quiescence. Here, analyses of Lmo2 transgenic mice, patient-derived xenografts and single-cell RNA-sequencing data from primary ETP-ALL identified a rare subpopulation of leukemic stem cells expressing high levels of the cytokine receptor FLT3. Despite a highly proliferative state, these FLT3-overexpressing cells had long-term self-renewal capacity and almost complete resistance to chemotherapy. We found that FLT3 and its ligand may be direct targets of the LMO2 stem-cell complex, thereby establishing an autocrine FLT3 signalling loop that could be targeted by the FLT3 inhibitor gilteritinib. Consequently, gilteritinib impaired in vivo growth of ETP-ALL and improved the response to chemotherapy. Furthermore, gilteritinib synergized with the BCL2 inhibitor venetoclax, which may enable ‘chemo-free’ treatment of ETP-ALL. Together, these data provide a cellular and molecular explanation for enhanced cytokine signalling in LMO2-driven ETP-ALL beyond activating mutations and a rationale for clinical trials of FLT3 inhibitors in ETP-ALL.
- Open Access
Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells in vivo
Hypomethylating agents are used as frontline therapy for myelodysplastic neoplasms (MDS), but clinical response is unpredictable. To determine whether response was associated with in vivo dynamics of DNA hypomethylation, we conducted a phase 2 trial for MDS using both injection and oral azacitidine (AZA). We established that global DNA methylation levels in peripheral blood and bone marrow mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, there were distinct baseline and early drug induced differences in CpG methylation in haematopoietic stem and progenitor cells (HSPCs) in responders compared to non-responders that overlapped with regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. Following six cycles of therapy when clinical response typically manifests, differential hypomethylation in responder HSPCs pointed to marrow adaptation as a driver of enhanced haematopoiesis. Taken together, CpG methylation differences in HSPCs may explain variable response to AZA.
Open AccessClinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells in vivo
Hypomethylating agents are used as frontline therapy for myelodysplastic neoplasms (MDS), but clinical response is unpredictable. To determine whether response was associated with in vivo dynamics of DNA hypomethylation, we conducted a phase 2 trial for MDS using both injection and oral azacitidine (AZA). We established that global DNA methylation levels in peripheral blood and bone marrow mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, there were distinct baseline and early drug induced differences in CpG methylation in haematopoietic stem and progenitor cells (HSPCs) in responders compared to non-responders that overlapped with regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. Following six cycles of therapy when clinical response typically manifests, differential hypomethylation in responder HSPCs pointed to marrow adaptation as a driver of enhanced haematopoiesis. Taken together, CpG methylation differences in HSPCs may explain variable response to AZA.
- Open Access
- 21 June 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (14) , 3084
Author Correction: The immune response to RNA suppresses nucleic acid synthesis by limiting ribose 5-phosphate
- 21 June 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (14) , 3084
Open AccessAuthor Correction: The immune response to RNA suppresses nucleic acid synthesis by limiting ribose 5-phosphate
- Open Access
- 6 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (8)
Ki67 deficiency impedes chromatin accessibility and BCR gene rearrangement
The proliferation marker Ki67 has been attributed critical functions in maintaining mitotic chromosome morphology and heterochromatin organization during the cell cycle, indicating a potential role in developmental processes requiring rigid cell-cycle control. Here, we discovered that despite normal fecundity and organogenesis, germline deficiency in Ki67 resulted in substantial defects specifically in peripheral B and T lymphocytes. This was not due to impaired cell proliferation but rather to early lymphopoiesis at specific stages where antigen–receptor gene rearrangements occurred. We identified that Ki67 was required for normal global chromatin accessibility involving regulatory regions of genes critical for checkpoint stages in B cell lymphopoiesis. In line with this, mRNA expression of Rag1 was diminished and gene rearrangement was less efficient in the absence of Ki67. Transgenes encoding productively rearranged immunoglobulin heavy and light chains complemented Ki67 deficiency, completely rescuing early B cell development. Collectively, these results identify a unique contribution from Ki67 to somatic antigen–receptor gene rearrangement during lymphopoiesis.
- 6 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (8)
Open AccessKi67 deficiency impedes chromatin accessibility and BCR gene rearrangement
The proliferation marker Ki67 has been attributed critical functions in maintaining mitotic chromosome morphology and heterochromatin organization during the cell cycle, indicating a potential role in developmental processes requiring rigid cell-cycle control. Here, we discovered that despite normal fecundity and organogenesis, germline deficiency in Ki67 resulted in substantial defects specifically in peripheral B and T lymphocytes. This was not due to impaired cell proliferation but rather to early lymphopoiesis at specific stages where antigen–receptor gene rearrangements occurred. We identified that Ki67 was required for normal global chromatin accessibility involving regulatory regions of genes critical for checkpoint stages in B cell lymphopoiesis. In line with this, mRNA expression of Rag1 was diminished and gene rearrangement was less efficient in the absence of Ki67. Transgenes encoding productively rearranged immunoglobulin heavy and light chains complemented Ki67 deficiency, completely rescuing early B cell development. Collectively, these results identify a unique contribution from Ki67 to somatic antigen–receptor gene rearrangement during lymphopoiesis.